Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide

A strategy for the linear synthesis of a sialylated glycolipopeptide cancer vaccine candidate has been developed using a strategically designed sialyl-Tn building block and microwave-assisted solid-phase peptide synthesis. The glycolipopeptide elicited potent humoral and cellular immune responses. T...

Full description

Saved in:
Bibliographic Details
Published inChemical communications (Cambridge, England) Vol. 51; no. 50; pp. 10214 - 10217
Main Authors Thompson, Pamela, Lakshminarayanan, Vani, Supekar, Nitin T., Bradley, Judy M., Cohen, Peter A., Wolfert, Margreet A., Gendler, Sandra J., Boons, Geert-Jan
Format Journal Article
LanguageEnglish
Published CAMBRIDGE Royal Soc Chemistry 01.01.2015
Subjects
Amino Acid Sequence
Animals
Cancer
Cellular
Chemistry
Chemistry Techniques, Synthetic
Chemistry, Multidisciplinary
Glycopeptides
Glycopeptides - chemistry
Humans
Molecular Sequence Data
Mucin-1 - chemistry
N-Acetylneuraminic Acid - chemistry
Peptides
Physical Sciences
Science & Technology
Strategy
Synthesis
Vaccines
Vaccines, Synthetic - chemistry
Vaccines, Synthetic - immunology
BREAST-CANCER
TOLL-LIKE RECEPTOR-2
ANTICANCER VACCINE
SOLID-PHASE SYNTHESIS
ABERRANTLY GLYCOSYLATED MUC1
ANTITUMOR VACCINES
TUMOR-CELLS
CARBOHYDRATE ANTIGENS
T-CELL EPITOPE
ALPHA-SIALOSIDES
Online AccessGet full text

Cover

More Information
Summary:A strategy for the linear synthesis of a sialylated glycolipopeptide cancer vaccine candidate has been developed using a strategically designed sialyl-Tn building block and microwave-assisted solid-phase peptide synthesis. The glycolipopeptide elicited potent humoral and cellular immune responses. T-cells primed by such a vaccine candidate could be restimulated by tumor-associated MUC1.
Bibliography:NIH RePORTER
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1359-7345
1364-548X
DOI:10.1039/c5cc02199e